Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development

SAN FRANCISCO–(BUSINESS WIRE)–Prellis Biologics, Inc (Prellis Bio), a biotherapeutics company, today appointed Michael Nohaile, PhD as its new CEO and announced it has raised a $35 million Series C funding round, co-led by Celesta Capital and Avidity Partners with participation from Khosla Ventures, SOSV, True Ventures, and Lucas Venture Group. dr. Nohaile joins from Generate … Read more

Leukemia vulnerability discovered causing drug sensitivity

All human tumors originating from various tissues share a series of properties that define them, including the ability to prevent cell death. Instead, healthy organs induce programmed cell death or apoptosis to balance their size and eliminate damaged cells. There is a specific and physiological cell death called ferroptosis that occurs induced by the oxidation … Read more

Teaching an old drug new tricks

To treat some of the psychosis issues associated with Parkinson’s disease, physicians often prescribe pimavanserin, an antipsychotic drug that acts within the brain to prevent hallucinations and delusions. Because of its ability to prevent or reduce these symptoms, pimavanserin has also been studied as an antipsychotic treatment for other neurological conditions such as Alzheimer’s disease, … Read more

FDA Issues Final Guidance on Drug and Biological Instructions for Use (IFU)

On July 15, 2022, the Food and Drug Administration (FDA) issued its final guidance on developing the content and format of patient Instructions for Use (IFU) for human prescription drug and biological products, as well as drug-led or biologic-led combination products submitted under a new drug application (NDA) or a biologics license application (BLA). The … Read more

FDA Issues Final Guidance On Drug And Biological Instructions For Use (IFU) – Life Sciences, Biotechnology & Nanotechnology

22 July 2022 Sheppard Mullin Richter & Hampton To print this article, all you need is to be registered or login on Mondaq.com. On July 15, 2022, the Food and Drug Administration (FDA) issued its final guidance on developing the content and format of patient Instructions for Use (IFU) for human prescription drug … Read more

FDA Issues Final Guidance on Drug and Biological Instructions for Use (IFU) | Sheppard Mullin Richter & Hampton LLP

On July 15, 2022, the Food and Drug Administration (FDA) issued its final guidance on developing the content and format of patient Instructions for Use (IFU) for human prescription drug and biological products, as well as drug-led or biologic-led combination products submitted under a new drug application (NDA) or a biologics license application (BLA). The … Read more

Recursion is Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis

SALT LAKE CITY, July 21, 2022 / PRNewswire / – Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that the European Commission has granted Recursion Orphan Drug Designation for REC-4881 for the potential treatment of familial adenomatous polyposis (FAP). REC-4881 is an orally bioavailable, non-ATP-competitive allosteric small molecule … Read more

Research shows investigational drug fosters nerve repair after injury – BIOENGINEER.ORG

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of damaged nerves after spinal trauma. Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of damaged nerves … Read more

Why a Widely Used Drug Causes Birth Defects and Autism

Researchers discovered how valproic acid, a medication commonly used to treat epilepsy, migraines, and bipolar disorder, causes birth defects when taken during pregnancy. Researchers determined that valproic acid prevents nervous system cells from properly developing and dividing When used during pregnancy, the drug valproic[{” attribute=””>acid, which is used to treat bipolar disorder, migraines, and epilepsy, … Read more

Rady Children’s Institute for Genomic Medicine to participate in World Orphan Drug Congress panel on genomic newborn screening – BIOENGINEER.ORG

SAN DIEGO, Calif. – July 11, 2022 – Rady Children’s Institute for Genomic Medicine® (RCIGM) today announced that Wendy Benson, Chief Strategy and Innovation Officer, will participate in the panel discussion, “Developing a Shared Approach to Implementing Genomic Newborn Screening (gNBS) to Transform the Diagnostic and Therapeutic Odysseys of Children with Rare Inheritable Diseases ”at … Read more